Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

The main goal was to measure at six months the change in the apnea-hypopnea index, a scale used to measure the breathing reductions or interruptions during sleep (the higher the score, the more ...

Greater obstructive sleep apnea (OSA)-related hypoxemia is associated with frontoparietal cerebrovascular pathology, which is linked to reduced medial temporal lobe (MTL) integrity and impaired ...

At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an AHI ...

defined as achieving at least a 50% reduction in apnea-hypopnea index. Results from the pivotal OSPREY trial for LivaNova’s aura6000 system demonstrated promising 12-month data in patients with ...

PSG-derived OSA variables included the apnea-hypopnea index, total arousal index, and minimum oxygen saturation. At an earlier time point, magnetic resonance imaging was used to assess global and ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

AD109 met the primary endpoint, mean change in apnea-hypopnea index (AHI, p=0.001) at 26 weeks, across a broad range of people with mild, moderate and severe obstructive sleep apnea Study ...

The researchers analyzed variables related to sleep apnea such as apnea-hypopnea index (AHI), total arousal index and a Hypoxemia Severity Index where lower SpO2 indicated more severe hypoxemia.